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EFFECT OF MALARIA ON HIV VIRAL LOAD AND MATERNAL OUTCOMES IN HIVPOSITIVE PREGNANT WOMEN OF ACCRA, GHANA
Jana Halfon, Elizabeth Levey, Margaret Lartey, Richard Adanu, Michael Ntimi, Larysa Aleksenko,
Kwamena Sagoe, Patrick Kumi, Michael Cappello, and Elijah Paintsil (Sponsored by Elijah Paintsil, Yale
School of Medicine, through the Doris Duke Charitable Foundation)
HIV-1 positive pregnant women co-infected with malaria face increased risk of Mother-to-childtransmission (MTCT) of HIV. Placental malaria has been implicated, whether through an increase in
placental or peripheral HIV viral load or a disruption of placental architecture. But the mechanism is not
well understood. There are no studies in West Africa, where HIV and malaria co-infection is prevalent.
We determined whether reported malaria infection in HIV-1 positive pregnant women affects
either peripheral or placental HIV viral load. Establishing how malaria affects HIV-positive pregnancies in
this population is of public health significance.
130 HIV-positive pregnant women in their third trimester were recruited at the Korle-Bu Teaching
Hospital in Accra, Ghana from 2007 to 2009 and followed prospectively until delivery. Of 130 recruited,
65 delivered at Korle-Bu. HIV-1 RNA concentration of peripheral and placental blood samples were
measured using Amplicor HIV-1 Monitor version 1.5. Giemsa-stained peripheral and placental thick blood
films were analyzed for malaria parasitemia. Periumbilical and peripheral full-thickness placental tissue
biopsies were fixed, stained with Giemsa and H&E, and assessed by a pathologist blinded to subject data.
The overall mean peripheral and placental HIV-1 viral loads were 5045 copies/ml (SD 16014) and
3389 copies/ml (SD 10679), respectively. No significant effect was seen between subjects reporting and not
reporting malaria during pregnancy. Significance was seen in the effect of 2 or more doses of intermittent
preventative treatment on reducing incidence of malaria (p<0.0001) and in the effect of combination
antiretroviral therapy in reducing HIV viral load compared to single-dose NVP at delivery (p=0.05).
The low mean HIV-1 viral loads in this population may be responsible for the low rate MTCT at
Korle-Bu (0.3 percent, unpublished data). The low rate of transmission warrants further research on the
local placental factors influencing transmission. Aggressive antimalarial and antiretroviral therapies are
having a significant impact on reducing risk of developing clinical malaria and risks of MTCT of HIV, but
better widespread access to care is still needed.
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“In much of the world, the most dangerous thing a woman can do is become pregnant.”
-- Nicholas Kristof, Half the Sky

I.

INTRODUCTION
Maternal morbidity and mortality continue to be one of the most important global

health issues, particularly in sub-Saharan Africa, home to half of all maternal deaths.
According to the World Health Organization (WHO), 19 of the 20 countries ranked
highest in maternal mortality ratios are in sub-Saharan Africa, where the maternal
mortality rate averages between 920 to 1050 per 100,000 live births.1,2 In underdeveloped
nations, maternal mortality rates have changed very little in the past 15 years and only
about 33% of all maternal deaths are prevented. 1 In addition, for every woman who dies
from obstetric causes, close to 20 more suffer injury, infection or disease – nearly 10
million women each year. 2 But women are not the only population that suffers from high
maternal death rates. Motherless children in the developing world are ten times more
likely to die within the first two years of life. 2 Social development and well-being also
suffer. The old African saying, “If you take all the men out of a village, nothing will
change; if you take all the women out, the village will not survive,” applies. Women are
the backbone of society in sub-Saharan Africa, rearing the children, managing the
household, feeding the village. Many believe that the women of the developing world
could play a major role in ending the cycle of poverty. 49 It is, therefore, of paramount
importance to reduce maternal morbidity and mortality on the African continent -- for
women, children, and sustainability of most African society.
Within the 60% of preventable deaths in sub-Saharan Africa, there are five

2
complications that account for over 70% of all maternal morbidity.

2

Hemorrhage

continues to be the leading cause of mortality in the developing world, accounting for
25% of all maternal deaths and up to 46% in some populations in West Africa. 4 Other
causes include unsafe abortion (13%), eclampsia (12%), and obstructed labor (8%). A
contributing factor to all these causes is, of course, access to care. Better access to care
would reduce deaths due to obstructed labor and eclampsia. Better resources could
prevent so many fatal maternal hemorrhages.
Complications from infectious diseases during pregnancy is the second leading
cause of maternal mortality in sub-Saharan Africa, accounting for nearly 15% of all
maternal deaths. 4 The HIV pandemic continues to devastate this region, accounting for
more than 70% of the world’s 40 million HIV-1 infected individuals. 7 And, like maternal
mortality, this region accounts for a disproportionate number of the world’s HIV infected
women, more than 80%.3
But though HIV is more notorious, malaria remains the most prevalent infectious
disease affecting sub-Saharan Africa, and the most preventable. 2 In the adult population,
women are at higher risk of malaria infection than men, and pregnant women are at more
risk than non-pregnant women.20 Up to 66% of pregnant women in sub-Saharan Africa
are infected with malaria.17 Thus, it is clear that both diseases significantly increase risk
of maternal morbidity and mortality. But the effect of co-infection of the two diseases is
still largely unknown.
A.

Overview of HIV in Pregnancy

Among pregnant women in sub-Saharan Africa, HIV prevalence rates can exceed
40%.3 The most significant risk of an HIV-positive pregnancy is the risk to the future
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child, specifically risk of mother-to-child transmission of the HIV virus. Mother-to-child
transmission (MTCT) of HIV-1 continues to be a major global health issue, particularly
in resource-limited countries such as those of sub-Saharan Africa. According to WHO
statistics, an estimated 420,000 children were infected with HIV-1 in 2007, over 90% of
which acquired via MTCT.2,4 HIV-infected infants have a higher risk of mortality than
HIV-uninfected infants, but even uninfected infants who were exposed to HIV have a
much higher risk of mortality than infants unexposed.

50

Reducing HIV infection in

women of the developing world is a complex, multifaceted undertaking with mixed
success. Reducing risks of MTCT, on the other hand, can be highly successful.
Vertical transmission of HIV can occur in the prenatal, intrapartum, or postpartum
period, but 50 to 80% of all transmissions are thought to occur during the time period
near or during delivery.6, 51 Four main factors contribute to the risk of MTCT: 1) high
maternal viral load of HIV RNA at time of delivery, 2) prolonged exposure to vaginal
secretions during prolonged labor, 3) micro-disruption of placental integrity leading to
exposure of fetus to maternal blood, and 4) transmission of HIV through breast milk
(postpartum risk). 51 Interventions specifically targeted to each of these four factors have
resulted in a dramatic reduction of MTCT.
Antiretroviral therapy has been the cornerstone of reducing maternal HIV RNA
viral load, the single most important risk factor for MTCT. In 1994, the Pediatric AIDS
Clinical Trials Group (PACTG) protocol 076 demonstrated that a three-part regimen of
zidovudine (AZT) given during the prenatal and antepartum period (as well as to the
neonate) resulted in a 67% decrease in rate of MTCT. 51,52 The regimen begins at 14 to 34
weeks gestation and continues throughout the pregnancy, with a boost of intravenous
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AZT during labor until delivery.

52

The goal is to reduce HIV RNA viral load to

undetectable levels, or at minimum, to below 1000 copies/mL. Studies have shown that
HIV RNA viral loads above this cut-off carry a 12-fold increased risk of vertical
transmission. 53
For women with viral loads above 1000 copies/mL, elective caesarian sections have
been shown to reduce MTCT of HIV. One study found that elective caesarians in women
with >1000 copies/mL HIV RNA reduced the risk of MTCT by 90% compared to vaginal
delivery or emergency caesarian.

53

Elective caesarian sections reduce the risk of

prolonged labor through decreased exposure of fetus to vaginal secretions in the birth
canal and decreased microtransmission of maternal blood during uterine contractions.
Elective caesarians also reduce the risk of chorioamnionitis, a result of prolonged labor
and another factor that may increase risk of MTCT of HIV. 51
Lastly, avoidance of breastfeeding eliminates the final risk of vertical transmission
of HIV to the child. In the developed world, resources exist to supply new mothers who
are HIV-positive with replacement formula, but in the developing world, these resources
are scarce or financially infeasible. In Ghana, for example, the rate of exclusive
breastfeeding in HIV-positive mothers is more than 40%, according to National Data.16
The risk of transmitting HIV is weighed against the risk of malnutrition to or starvation
of the infant, and in most developing nations, mothers risk HIV transmission in order to
feed their new child. Though this topic is of great global significance, as avoidance of
breastfeeding is the most preventable risk factor associated with MTCT, it will not be
discussed here.
Implementation of the above protocols have reduced the rate of MTCT in the
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developed world to less than 2%.3 In 2007, for example, only 67 children were born with
HIV in the United States.

54

In the developing world, however, these interventions are

difficult to achieve. Without intervention, rates of MTCT can reach 45%.

3

In sub-

Saharan Africa, for example, most pregnant women do not have access to prenatal care or
counseling, and availability of highly active antiretroviral therapy (HAART) and
caesarian delivery is limited. In areas with poor medical infrastructure, the three-part
AZT regimen is too expensive and complex for implementation. Abbreviated antiretroviral regimens (ARV), on the other hand, have been more successful. These simpler
and less expensive regimens have been shown to effectively reduce perinatal
transmissions in resource-limited countries, significantly reducing the maternal viral load
at delivery and therefore decreasing the risk of transmission.

5, 10-14

There are different

permutations of regimens, but the most popular regimen is single-dose nevirapine (NVP)
administered to the mother at the onset of labor and to the infant between 48-72 hours of
life.2 This is not the most efficacious regimen, but it is the most cost-effective and
feasible.50 Even then, it is estimated that only 33% of HIV-positive pregnant women
receive any antiretroviral treatment, suggesting that increased access to care would have a
profound effect on reducing MTCT worldwide.2
For areas that can afford it, first line therapy should be the additional administration
of AZT and lamivudine from 28 weeks gestation to delivery and administration of a oneweek course of AZT to the infant. Lamivudine is added to reduce risk of HIV resistance
to single-dose NVP.

50

Interestingly, HIV resistance does not appear to develop in

subsequent pregnancies to single-dose NVP. In addition, the serious side effect of
hepatotoxicity with nevirapine use has not been observed in women receiving only
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single-dose nevirapine during labor for prevention of mother to child transmission.

55

Therefore, in the developing world, the benefit of using single-dose NVP far outweighs
the risks.
It must also be mentioned that the first step to effectively reducing MTCT rates of
HIV in any population is successful identification of pregnant women infected with HIV.
This requires widespread and targeted prenatal testing and counseling to all pregnant
women through prevention of mother-to-child transmission (PMTCT) programs. With
effective programs and basic resources available to identified HIV-positive pregnant
women, low rates of MTCT can be achieved, even in developing nations.54 Reducing risk
factors to MTCT is the goal of every obstetrician, but recently a new risk factor has been
identified that requires even further intervention, a risk factor that affects nearly 50
million pregnant women on the African continent.2 That risk factor is malaria.
B.

Overview of Malaria in Pregnancy

Though more focus has been placed on the HIV epidemic in sub-Saharan Africa,
malaria is also recognized as a major global health issue. There were approximately
881,000 malaria deaths in 2006, of which 91% were in Africa and 85% were children
under 5 years of age.54 It is estimated that 10,000 women and 200,000 infants die each
year as a result of malaria infection during pregnancy.54 Malaria, predominately the
Plasmodium Falciparum species, can lead to severe maternal anemia during pregnancy,
prematurity, and low birth weight, all of which contribute to infant mortality in subSaharan Africa.54 Parasitemia peaks in the second trimester in both primigravidas and
multigravidas, but the increased risk for pregnancy-associated malaria (PAM) persists for
60 days postpartum.20 Thus, malaria during pregnancy is of great global significance,
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adversely affecting maternal and neonatal outcomes.
As stated before, pregnant women have the highest risk of developing malaria
symptoms than any other adult population in sub-Saharan Africa.20 The reason for this is
one of the unique features of the P. Falciparum malaria parasite.

Pregnancy

selects

for a specific population of parasites that express variant surface antigens (VSA).21
These antigens adhere parasite-infected erythrocytes to chondroitin sulfate A (CSA) on
the syncytiotrophoblast lining in the intervillous spaces of the placenta. The process of
selection appears to be mediated by upregulated transcription of the var2csa gene.

21

Adherence of parasite-infected erythrocytes to the placental lining leads to sequestration
of leukocytes and a local inflammatory response, mediated by numerous cytokines and
transcription factors, which will be discussed in the next section.22 This response can
cause a disruption of placental architecture through local necrosis and syncytial
degradation, and thus increase the risk of low-birth weight infants and possible fetal
infection through breakdown of placental architecture.23 In an woman co-infected with
HIV, this could possibly lead to microtransmission of maternal blood and entry of the
virus.
Multiple studies have established that primigravidas are most at risk for malaria,
with prevalence decreasing with increasing gravity.18,19 This is particularly true in malaria
endemic countries, where women have an overall high immunity to malaria but have not
developed specific antibodies to placental antigens until after their first pregnancy. The
specific antibodies that develop are anti-VSA IgG immunoglobulins, and they have a
protective effect against placental malaria during subsequent pregnancies. These
antibodies prevent cytoadherence of the infected erythrocytes to the placenta, and thus
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reduce the risk of placental destruction.

21

In women with HIV, however, the reduced

immunity may nullify the ability of the body to mount a response against the malaria
parasite with anti-VSA IgG.33, 37 Interestingly, though, one recent study demonstrated that
decreased levels of anti-VSA IgG were not associated with increased rates of clinical
malaria or adverse maternal or infant outcomes in HIV-positive pregnant women,
suggesting that several other mechanisms are at play.56 It seems clear that the interaction
of malaria and HIV in co-infected pregnant women of sub-Saharan Africa is a complex
process that is not entirely understood.
C.

Co-infection of HIV and Malaria in Pregnancy

In 2004, the WHO identified the prevention of malaria during pregnancy as a
necessary tool in limiting maternal morbidity and mortality, particularly in HIV-positive
individuals.2 The relationship between malaria and HIV was known beforehand, as
several studies suggest that the interplay of the two infections seems to fuel the continued
spread of both diseases.

24-30

HIV diminishes immunity thereby increasing the risk of

malaria infection and the development of clinical malaria.24-26 Conversely, malaria has
been show to increase HIV replication by activating the immune system by mechanisms
similar to that found with vaccination and bacterial infections.27-30 The interplay of the
two infectious diseases is also clearly seen during pregnancy. One study demonstrated
that HIV-1 positive pregnant women with peripheral malaria parasitemia had a two-fold
higher HIV-1 plasma concentration than those HIV-positive pregnant women without
malaria infection, when matched for initial HIV-1 viral load prior to infection.31 Other
studies have demonstrated that co-infection of HIV and malaria is associated with an
increased risk of higher parasitemias, maternal death, postpartum maternal anemia, and
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severe clinical disease compared to HIV-negative women.

37, 57

. Placental and clinical

malaria are more common in HIV-positive women, as are cases of infant and maternal
death.

3,32

Recently, one additional parameter to the relationship between HIV and

malaria in pregnancy has emerged: the potential risk of increasing MTCT.
The studies addressing the effect of malaria parasitemia on MTCT of HIV are,
unfortunately, conflicting. The relationship was first identified in a study in Cameroon,
where researchers found higher MTCT rates correlated with peak rainy seasons and with
higher malaria transmission, suggesting an association between MTCT and higher rates
of malaria during pregnancy.3 In Uganda, researchers found a significant increase in
vertical HIV transmission associated with placental malaria.

34,35

However, a study in

Mombasa, Kenya found no impact of placental malaria on MTCT.36 And lastly, a study
in Kisumu, Kenya found an increased risk of MTCT only at high maternal parasitic
densities compared with low parasitic densities.37 It has been proposed that significant
discrepancies in methodological approaches to defining placental malaria in the Kenya
studies can account for differences in outcome, but further studies are needed to confirm
the role of malaria infection on HIV-1 vertical transmission and the mechanisms at play.
As discussed before, the interaction of malaria and HIV in pregnancy is complex,
particularly at the level of the placenta. Two main mechanisms have been proposed to
explain the risk of placental malaria on MTCT of HIV: 1) increased HIV-1 viral load and
2) disruption of placental architecture. The first involves the relationship between malaria
infection and increased HIV RNA viral replication. Malarial infection results in a
temporary increase in HIV RNA, an increase that will return to baseline after two months
of antimalarial treatment. 27, 41 However, a transient rise in HIV RNA viral load during
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the last trimester could increase the risk of MTCT.

27,3,34

But a recent analysis by

Brahmbhatt et al demonstrated that even after adjusting for maternal HIV viral load,
placental malaria significantly increased the risk of MTCT, suggesting that increased
HIV-1 viral concentration is not the sole mechanism for transmission.35
As mentioned previously, numerous cytokines and transcription factors mediate the
local inflammatory response induced by sequestration of malaria in the placenta. Thus, it
is possible that these factors could increase risk of MTCT by affecting the local placental
environment, but little data is available and the studies that have been done are
heterogenous. For example, in vitro studies of placental co-infection of HIV-1 and
malaria have shown dose-dependent increases in local HIV-1 viral replication related to
increased expression of TNF-alpha, a pro-inflammatory cytokine.32 However, another
study found significantly reduced placental viral load compared to peripheral viral load
among women with confirmed placental malaria, despite high levels of TNF-alpha.38
Other studies have identified cytokines and factors induced by placental malaria presence
with a more protective role against MTCT. One study suggests that placental malaria
induces an upregulation of Th1 cytokine interferon-gamma in the intervillous blood
mononuclear cells, which are known to reduce HIV replication.37 Leukemia inhibitory
factor, which inhibits HIV replication, has been shown to be upregulated in women with
placental malaria who do not transmit vertically.58 Studies have also shown that placental
malaria can increase expression of macrophage inflammatory protein 1-Beta, which
blocks HIV entry into cells.59
Thus, it appears that there is much controversy surrounding both proposed
mechanisms for the effect of placental malaria on MTCT of HIV. Does placental malaria
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protect against MTCT or promote it? Are there cytokine or immune targets we can use to
reduce the risk of vertical transmission of HIV? Can we identify specific placental
immune factors in HIV-positive women who do not transmit? Do these same factors lead
to adverse maternal outcomes? Understanding the mechanism by which HIV and malaria
interact is incredibly important to answering these questions.
D.

Prevention of Malaria in Pregnancy

Due to the high risk of maternal morbidity and infant mortality associated with
pregnancy-associated malaria, the WHO identified malaria prevention as an essential
component of prenatal care among all pregnant women in areas of stable P. falciparum
transmission in Africa.39,40,54

Specifically, the WHO recommends use of insecticide-

treated bednets (ITN) and intermittent preventive treatment (IPT) during the course of the
pregnancy. A curative dose of sulfadoxine-pyrimethamine (SP, Fansidar) administered
twice at monthly intervals after the first trimester is the preferred method of prophylaxis
for HIV-negative pregnant women.54 Though toxicity due to the sulfa component can
occur, SP’s low cost, relative safety, ease of use, and efficacy outweigh adverse effects.39
This two-dose regimen of IPT with sulfadoxine-pyrimethamine significantly reduced the
incidence of placental malaria, LBW, and maternal anemia in women having a first or
second pregnancy, even in areas where the prevalence of drug resistance was 19 to 26
percent.41
For HIV-positive pregnant women, at least three or more doses of IPT is needed to
prevent placental malaria.2 Numerous studies showed that while two doses of IPT with
sulfadoxine-pyrimethamine was sufficient for HIV-negative women, more frequent
dosing was needed in HIV-positive women to achieve the same effect.41 Monthly IPT
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dosing was significantly more effective than the two-dose regimen, as supported by a
lower rate of placental malaria and an increase in birth weight, even in areas where the
prevalence of drug resistance was as high as 39 percent. In HIV-negative women,
monthly dosing did not improve outcomes over the two-dose regimen. 41
The more aggressive IPT regimens required for HIV-positive pregnant women
supports the unique relationship between HIV and malaria co-infection during pregnancy,
and the need to understand that relationship. In addition the scientific implications,
understanding this relationship has significant policy implications towards the
development of additional targeted, cost-effective strategies to reduce adverse maternal
and infant outcomes. Are more funding and efforts needed to prevent placental malaria
infection in HIV-positive pregnant women or will more access to ARV treatments have a
greater effect? In resource-limited environments, these are highly important questions
that need to be answered.
E.

Overview of Ghana

No previous study has investigated the relationship of HIV and malaria co-infection
among pregnant women of Accra, Ghana. The Republic of Ghana is located in West
Africa on the Coast of Guinea with a population of almost 24 million people. Accra is the
capital of Ghana and has a population of about 3 million people. Compared to the rest of
sub-Saharan Africa, HIV/AIDS rates in Ghana have remained relatively low and stable,
rising from an estimated 2.4% in 1992 to 3.1% in 2004.16 In 2006, government-sponsored
programs such as HIV testing and counseling sites and Prevention of Mother-to-Child
Transmission (PMTCT) sites were increased in number throughout the country, including
at Korle-Bu Teaching Hospital in Accra, Ghana. This reduced the national HIV
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prevalence rate from 3.1% in 2004 to 1.9% in 2007. Among pregnant women, the 2007
prevalence rate of HIV was slightly higher at 2.6% on average, 3.4% in urban locations,
and there were 3,000 new infections among children in 2007.16
Ghana is holoendemic for malaria and has a stable rate of malaria transmission. It is
perennial but peaks during the rainy and post-rainy season (June to August).

P.

falciparum causes over 98% of all malaria infections.
The low prevalence rate of HIV but stable rate of malaria transmission make Ghana
an interesting comparison study to the previous studies on malaria and MTCT in Eastern
and Southern Africa, where HIV prevalence rates can reach up to 20% in some areas. 34-37
The location of the study at the Korle-Bu Teaching Hospital is also an interesting
comparison to the rural environments of most of the previous studies. Korle-Bu is a
tertiary hospital and the largest teaching hospital in Western Africa. The hospital has
1600 inpatient beds and several thousand outpatient visits a year. It also serves as the
primary teaching hospital for University of Ghana Medical School. It is the referral center
for all high-risk pregnancies, complicated pregnancies (including gestational diabetes,
hypertension in pregnancy, or other comorbid diseases), and pregnancies in the third
trimester in the Greater Accra and Eastern Region. Thus, it is the highest level of care
available for the average Ghanaian woman who becomes pregnant in these areas.

II.

STATEMENT OF PURPOSE
The first specific aim (1) was to determine the prevalence of P. falciparum

parasitemia in peripheral blood of HIV-1 negative and positive pregnant women
attending antenatal clinic (ANC) at Korle-Bu Teaching Hospital in Accra, Ghana. It was
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our hypothesis that HIV-1 positive women would have higher incidence of malaria
parasitemia in comparison to HIV-1 negative women during pregnancy.
The second specific aim was two-fold. One aspect of that aim (2a) was to compare
the intensity of P. falciparum parasitemia in the peripheral blood and placenta of HIV-1
positive women with or without clinical malaria at delivery. It was our hypothesis that
there would be a high density of parasitemia in both blood and placenta, especially in
women with clinical malaria. The other aspect of the second aim (2b) was to determine if
placental P. falciparum parasitemia was associated with increased peripheral HIV-1 RNA
concentration in HIV-1 positive women at delivery. It was our hypothesis that HIVpositive women with increased intensity of placental parasitemia would also have higher
HIV-1 RNA concentration in the peripheral blood.
The third specific aim (3) was to determine the incidence of HIV-positive infants
born to positive HIV-1 women with or without acute malaria infection. It was our
hypothesis that HIV-positive women with placental malaria would have a higher
incidence of HIV-1 positive infants.

III. METHODS
The project was a two-year pilot study to investigate the specific aims listed above.
Initial approval for the project was obtained through the Yale Institutional Review Board
(IRB) and the Ghana IRB.
There were four parts to the pilot study design. Part I involved initial recruitment of
both HIV-negative and HIV-positive subjects and the obtainment of demographic and
specific disease-related information as reported by the subjects in a questionnaire. Part I
also involved the obtainment of blood samples from the HIV-positive subjects at
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recruitment for thick blood smear, CD4 and viral load assessment. Part II involved the
postpartum period - the obtainment of information relating to delivery, blood samples
from the mother for thick smear and viral load assessment, and collection and processing
of the placentas from HIV-positive subjects. Part III was placental histopathological
analysis. Part IV was assessment of MTCT of HIV in the research population based on
HIV-DNA testing of infant blood samples.
A.

Background

The study was conducted at Korle-Bu Teaching Hospital in Accra, Ghana in five
different departments. Initial recruitment of the HIV-positive pregnant women occurred
at The Fevers Unit, the medical ward for patients with HIV, tuberculosis and other
infectious diseases. All patients who are treated at Korle-Bu and who test positive for
HIV-1 are referred to this department, including all HIV-1 positive pregnant women.
Further recruitment of HIV-positive pregnant women occurred in the Maternity Wards of
the OB-GYN department. Recruitment of HIV-negative pregnant women occurred at the
Antenatal Center (ANC) of the OB-GYN department.

All pregnant women receiving

care at Korle-Bu’s ANC are given a purple maternity booklet to carry with them at all
times. This booklet serves as the obstetric chart - documenting routine prenatal care,
medication use (including IPT administration), results of screening tests, and any medical
complications that occur during the pregnancy.

Demographic and disease-specific

information was obtained from this booklet. The National Health Scheme, Ghana’s
government healthcare system, provides free medical care for all pregnant patients,
including antiretroviral and antimalarial medications.
All women who have positive pregnancy tests and who are referred to Korle-Bu
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participate in the Prevention of Mother to Child Transmission (PMTCT) program.
Pregnant women are encouraged to obtain HIV testing and over 98% of pregnant women
agree to be tested (data not presented). If women test positive for HIV, they are referred
to the Fevers Unit to begin HIV care. At the Fevers Unit, blood samples are taken to
determine CD4 count.
B.

Consent

Two separate written consent forms were devised - one describing the procedure for
HIV-negative subjects, one describing the procedure for HIV-positive subjects. The
consent was written in English. If the subject did not speak English, a translator was
employed to explain the details of the consent. All subjects received a written copy of the
consent form and were asked to sign a separate form confirming that consent was
obtained. If subjects were unable to write, they provided their fingerprint, a common
practice among illiterate individuals in Ghana.
C.

The Questionnaire

A brief questionnaire was designed to obtain basic information regarding obstetric
history (past and present), socio-economic history, demographics, and disease-specific
history of both HIV and malaria exposure. The questionnaire was written in English. As
with the consent, if the subject did not speak English, a translator was employed.
D.

Inclusion/Exclusion Criteria

All HIV-positive pregnant women receiving care at the Korle-Bu Fevers Unit and
Maternity Ward were eligible. Women were ineligible if they were part of other research
studies, less than 18 years of age, or had hypertension or complications during pregnancy.
E.

Implementation
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Part I: Recruitment
130 HIV-positive pregnant women in their second or third trimester who were
eligible were recruited into the study at the Fevers Unit of Korle-Bu Teaching Hospital in
Accra, Ghana from October 2007 to May 2008 and then again from September 2008 to
April 2009. 57 subjects were recruited in the 2007-08 period and 74 were recruited in the
2008-09 period.
During the recruitment phase, the subjects were verbally consented and asked a
series of questions detailed in a questionnaire, utilizing a translator if necessary. Careful
documentation was made of current or prior treatment and time of diagnosis for both HIV
and malaria. Blood samples were obtained for initial viral load and CD4 count, and thick
blood films were prepared for malaria parasitemia analysis. Finally, a white sticker with
the research cell phone number and instructions to call if there were any questions was
placed on the maternity folder. The subjects were also encouraged to call when they
went into labor so that the research team could obtain the necessary samples and
information at delivery. The subjects were then followed prospectively until delivery.
124 documented HIV-seronegative pregnant women matched for age (+/-5 years),
gravity (1,2,3+), parity (0,1,2+), and gestational age (+/- 2 weeks) were recruited at the
Maternity Ward while waiting for their prenatal appointment. The HIV-negative subjects
were consented in the same fashion as the HIV-positive subjects and asked to answer the
same questionnaire. No blood samples were obtained, and the HIV-negative subjects
were not followed until delivery.
Part II: Delivery
When an HIV-positive subject had delivered, 3 blood samples were collected
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within 48 hours of delivery - one maternal peripheral blood sample for peripheral HIV-1
RNA viral load testing, one maternal peripheral thick film preparation for peripheral
malaria parasitemia analysis, and one blood sample from the infant for HIV-1 DNA
testing.
It was common to recruit subjects into the study at the time of delivery as several
HIV-positive pregnant women had been missed in the initial recruitment phase at the
Fevers Unit. If the subject had not been recruited prior to delivery, consent was obtained
and the questionnaire was given to obtain retrospective data. If the subject had been
previously recruited, follow-up questions regarding antiretroviral initiation, malaria
exposure and treatment, and additional IPT doses since recruitment were recorded.
All HIV-positive women delivering at Korle-Bu Hospital received a dose of
Nevirapine at the onset of labor. All infants born to HIV-positive women at Korle-Bu
also received a dose of Nevirapine within 72 hours of birth. According to 2003 WHO
guidelines on prophylaxis of HIV in infants born to HIV-positive mothers, infants would
receive additional antiretroviral combination therapy (Combivir) for one week if the
mother did not start antiretrovirals before 28 weeks gestation, and for 4 weeks if she did
not receive any antiretroviral therapy prior to delivery. 2
Part IIIa: Placental Processing and Examination
At delivery, the placenta was obtained and processed within 48 hours.
Periumbilical and peripheral full-thickness biopsies and membrane samples were taken,
placed into pencil-labeled cassettes, and fixed in formalin. The formalin-fixed, paraffinembedded placental disc tissue, including membranes and umbilical tissue, were then
sectioned

for

hematoxylin

and

eosin

staining

(H&E).

Giemsa

staining
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immunohistochemistry was also performed on the placental disc according to the
procedure outlined by Rogerson et al.42
Placenta architecture and malaria parasite presence were assessed by a pathologist
blinded to subject data. Presence of P. falciparum-infected erythrocytes and of malaria
pigment in fibrin and monocytes was noted. Using a systematic method, 500 intervillous
blood cells were counted under oil immersion, and classified as uninfected erythrocytes
(UE), infected erythrocytes (IE), or leukocytes, subdivided by morphology into
lymphocytes, polymorphs, or monocyte-macrophages. Histologic percentage parasite
density was defined as IE/(UE + IE), × 100%.

42

Of leukocyte types, only monocyte

counts varied between infected and uninfected placentas. A high prevalence of formalin
pigment precluded assessment of pigment that was due to chronic or past malaria
infection.

Malaria quantification was performed by parasitologists at The Noguchi

Institute, a prominent research facility located 45 minutes away from the Korle-Bu
campus. Parasite densities were calculated by assessing immunohistochemistry placental
slides at 203 magnification. Five random fields, each of 1 square mm of the placental
slides, were averaged to obtain density of parasites, expressed as number mm2.42
Part IIIb: Blood Sampling and Viral Load Assessment
Maternal blood samples were obtained and collected into EDTA tubes. Infant blood
samples were obtained in the same manner. CD4 assessment was performed at the
Central Lab of Korle-Bu, through the Fevers Unit. HIV-1 RNA concentration of maternal
peripheral and placental blood samples were measured using Amplicor HIV-1 Monitor
version 1.5 (Roche Diagnostics, Branchburg, New Jersey, USA) with a quantification
limit of 400 copies per milliliter.
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Part IV: HIV-1 DNA testing of infant samples
HIV-1 DNA testing of the infant were done using Amplicor HIV-1 Monitor version
1.5 (Roche Diagnostics, Branchburg, New Jersey, USA). An infant would be considered
HIV-1 positive and the mother a transmitter if HIV-1 DNA PCR testing was positive
within 48 hours of delivery, reflecting intrauterine and intrapartum transmission.
Thick Film Preparation and Analysis
Thick films were prepared from a single drop of blood evenly dispersed in a 2cmdiameter circle on a microscope slide using a needle tip, then dried overnight in a sealed
container and stained the next day. Both peripheral and placental thick blood films were
stained with 20% Giemsa for 10 minutes and examined under oil immersion for malaria
parasites. The Giemsa was prepared and films stained at the Microbiology Department of
Korle-Bu. The thick films were then analyzed for malaria parasitemia by two separate
parasitologists, one at Korle-Bu and one at Noguchi. A thick film was considered
negative if 100 microscopic fields showed no parasites.
F.

Statistical Methods

Specific aims 1 and 2a were evaluated using descriptive statistics and chi
square tests. Logistic regression was used to determine if placental P. falciparum
parasitemia was associated with increased peripheral and/or placental HIV-1 RNA
concentration in HIV-positive women at delivery (Specific Aim 2b). In the absence of
data from microscopy or histopathology identifying peripheral or placental malaria
parasitemia, reported data from the questionnaire of specific aim 1 was utilized as a
surrogate. Paired, one and two-tailed student t-test statistics were performed on the data
to determine differences in HIV-1 RNA viral loads among groups reporting and not
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reporting malaria. The data analyses were conducted using SPSS version 15.0 (SPSS Inc.
2006).
G.

Research Personnel

My purpose in the project was to continue the work begun by the previous Doris
Duke Fellow, fine tune the protocol, increase recruitment numbers, conclude the pilot
study, analyze the data, and assess further areas of research for future collaborations
between Korle-Bu Teaching Hospital and Yale School of Medicine. I recruited 74 HIVpositive pregnant women and 84 HIV-negative pregnant women into the study from
October 2008 to April 2009. Of the HIV-positive subjects, I personally collected and
processed 32 placentas, 45 maternal peripheral blood samples at delivery, and 15 infant
blood samples. I improved the attrition rate of placentas from 40% to 15% by the end of
the research period. I also made thick films at recruitment and delivery for all HIVpositive subjects that I recruited. I ran the maternal HIV-1 RNA viral load kits for the
available samples and sampled the placentas of the HIV-positive subjects. I was
responsible for the day-to-day implementation of the protocol of the pilot study from
2008-09 and for obtaining cooperation from the staff members of the different
departments. Finally, I performed the statistical analyses.
Viral processing was conducted at the Virology Lab with the assistance of that
department. Placental processing took place in the Pathology department with the
assistance of that department. Staining and reading of thick film slides for malaria
parasitemia took place in the Microbiology department and the Noguchi Institute of
University of Ghana, with the assistance of those two departments.
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IV. RESULTS
Part I and Part II of the research project were successfully completed at the
conclusion of the two-year pilot study. Processing and analysis of data pertaining to Part
III and Part IV have not yet been completed.
A total of 130 HIV-positive subjects were enrolled in the study. 79 delivered at
Korle-Bu, leaving 51 lost to follow-up (39%). Of the 79 who delivered at Korle-Bu,
peripheral blood samples were obtained for 60 (76%), placental data was available for 25
(32%), and infant blood samples were collected for 15 (19%).
Table 1 describes the demographic characteristics of the HIV-positive and HIVnegative subjects. In comparison to their HIV-positive counterparts, the HIV-negative
subjects were twice as likely to be educated at high school level or beyond (51% vs
26%), own their own home (36% vs 19%), work in a professional or office setting (24%
vs 9%), use a flush toilet versus an outside latrine or public toilet (45% vs 23%), and
have a faucet in the house for water (74% vs 48%).

Table 1: Demographic characteristics of Enrolled Subjects, by HIV status
HIV-1 positive

HIV-1 negative

N=130

N=124

31 (SD 6)

29 (SD 5)

None

21 (16%)

12 (10%)

Primary

18 (14%)

15 (12%)

Junior Secondary

55 (42%)

60 (48%)

Age (median)
Level of Education

P-Value
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HIV-1 positive

HIV-1 negative

P-Value

34 (26%)

63 (51%)

0.004

Own

25 (19%)

45 (36%)

0.02

Rent

78 (60%)

65 (52%)

Share

20 (15%)

12 (10%)

Married

109 (83%)

106 (85%)

Single

17 (17%)

16 (15%)

Professional

5 (4%)

11 (9%)

Office

4 (3%)

13 (10%)

Manual Labor

96 (74%)

82 (66%)

Unemployed

19 (15%)

17 (14%)

Flush Toilet

20 (23%)

56 (45%)

Pit Latrine in house

14 (11%)

6 (5%)

Public Toilet

33 (25%)

22 (18%)

Pit Latrine outside

43 (33%)

36 (29%)

Faucet in home

62 (48%)

92 (74%)

Outside Home

82 (63%)

20 (16%)

Secondary and above
Home

Marital Status

Occupation
0.05

Sanitation (%)
0.008

Water (%)

<0.0001

Table 2 describes the characteristics of HIV-positive subjects enrolled in the study.
Among the 130 HIV-positive pregnant women, 64% were diagnosed during the current
pregnancy. Of the subjects followed until delivery, 60% had started antiretroviral
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medication prior to or during the current pregnancy, and 42% received only nevirapine at
labor. The average birth weight of infants born to the HIV-positive subjects was 2.88 kg
(SD 0.55), and no significant difference in birth weight was found between subjects
reporting malaria and subjects not reporting malaria (2.80 vs 2.94, p=0.17). CD4 counts
taken within 6 months of delivery also did not differ between subjects reporting malaria
and subjects not reporting malaria (408 vs 452, p=0.63). Of the 13% of subjects whose
gestational age at delivery was less than 37 weeks, there was no significant difference in
subjects reporting or not reporting malaria.
Also of note, 53% of subjects did not know if their husband or partner was also
HIV-positive, 18% reported that their husbands or partners had tested negative for HIV,
and 26% reported that their husbands or partners had tested positive for HIV.

Table 2a: Characteristics of HIV-positive pregnant women, at enrollment
Enrolled
N=130
CD4 Baseline (median)

423

Diagnosis (%)
During current pregnancy

83 (64%)

Within year of pregnancy

17 (13%)

More than a year before pregnancy

29 (22%)

Antiretroviral (ARV) Use (%)
NVP at labour

53 (41%)

Combivir

8 (6%)

Combivir and NVP

68 (52%)
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Enrolled
Start of ARVs (%)
At labour

55 (42%)

At 28 wks gestation or after

35 (27%)

Before 28 wks gestation

12 (9%)

Before pregnancy

27 (21%)

Partner HIV-status (%)
Unknown

67 (53%)

HIV positive

34 (26%)

HIV negative

23 (18%)

Mode of Delivery (%)
SVD

43%

Elective Caesarian

46%

Emergency Caesarian

11%

GA at Delivery
>37 weeks

86%

34-36 weeks

5%

<34 weeks

8%

Subjects receiving NVP at onset of labor

100%

Antiretroviral Prophylaxis of Infants

NVP

50%

NVP + Combivir

50%
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Table 2b: Relationship of Malaria to Delivery Outcomes in HIV-positive subjects

Enrolled

No Malaria
Reported

Reported
Malaria

N=130

N=73

N=53

Birth Weight of Infant (mean)
(kg)

2.88 (SD
0.55)

2.94 (SD
0.62)

2.80 (SD
0.50)

CD4 Baseline (median)

423

408

359

NVP at labour

53 (41%)

12 (16%)

22 (42%)

Combivir

8 (6%)

7 (10%)

1 (1%)

Combivir and NVP

68 (52%)

51 (70%)

30 (57%)

>37 weeks

112 (86%)

62 (85%)

47 (86%)

34-36 weeks

7 (5%)

4 (6%)

2 (4%)

<34 weeks

10 (8%)

7 (9%)

4 (7%)

P-Value

0.17

ARV Use (%)
0.0006

GA at Delivery

0.37

Table 3 compares malaria characteristics between HIV-positive and HIV-negative
subjects. There was no significant difference in reported prevalence of malaria during
pregnancy between HIV-positive subjects (41%) and HIV-negative subjects (39%).
Among HIV-positive and HIV-negative subjects, there was no significant difference in
gravity or parity between subjects reporting malaria and subjects with no malaria reported
during their pregnancy. There was, however, a lower percentage of HIV-positive women
receiving more than 2 doses of IPT (23%) compared to HIV-negative women receiving 2
or more doses (31%), but this was not statistically significant (p=0.55). Among HIVpositive and HIV-negative groups receiving 2 or more doses of IPT, there was a
significant difference between the percent of subjects reporting malaria (70% and 71%
respectively) and subjects not reporting malaria (30% and 28% respectively). See Table
3b. Likewise, 13% of HIV-positive women reporting malaria received 2 or more doses of
IPT, whereas 60% received no IPT during pregnancy. No difference was noted in gravity
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or parity among women reporting malaria and not reporting malaria in either the HIVpositive or HIV-negative populations.
In terms of insecticide-treated bednet (ITN) use, over 75% of both HIV-positive
and HIV-negative groups did not utilize ITNs. But, within the HIV-positive group who
did use ITNs, 28% reported malaria compared to 72% who did not.

Table 3a: Characteristics of enrolled subjects, based on HIV status and Reported Malaria
Exposure

HIV-1 positive
All

HIV-1 negative

No
Reporte Hospital
Malaria
d
ized for
Reporte Malaria Malaria
d

N=130

N=73
(56%)

N=53
(41%)

Primagravidae

19
(15%)

11
(15%)

Secundigravidae

29
(22%)

21
(29%)

Multigravidae

77
(59%)

41
(56%)

36
(69%)

45
(35%)

27
(37%)

18
(36%)

27
(21%)

19
(26%)

53
(42%)

27
(37%)

26
(53%)

73
(56%)

39
(53%)

33
(62%)

N=15
(12%)

All

No
Reported Hospitali
Malaria Malaria zed for
Reporte
Malaria
d

N=124

N=75
(60%)

N=48
(39%)

N=9
(7%)

8 (15%) 2 (13%)

23
(19%)

13
(17%)

10 (21%) 3 (33%)

8 (15%) 2 (13%)

22
(18%)

16
(21%)

6 (13%)

11
(73%)

78
(63%)

46
(61%)

32 (67%) 5 (56%)

7 (47%)

42
(34%)

26
(35%)

16 (33%) 4 (44%)

8 (15%) 3 (20%)

28
(23%)

16
(21%)

12 (25%) 2 (22%)

5 (33%)

53
(43%)

33
(44%)

20 (42%) 3 (33%)

7 (47%)

52
(42%)

32
(43%)

20 (42%) 3 (33%)

Gravity

1 (11%)

Parity
Nulliparous

Primaparous
Multiparous
IPT SP Doses
0
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HIV-1 positive
1

27
(21%)

13
(18%)

30
(23%)

Yes
No

≥2

13
(25%)

HIV-1 negative
6 (40%)

32
(26%)

15
(20%)

17 (35%) 6 (66%)

21
(29%)

9 (17%) 2 (13%)

39
(31%)

28
(37%)

11 (23%)

0

29
(22%)

21
(29%)

8 (15%) 4 (27%)

15
(12%)

6 (8%)

9 (19%)

3 (33%)

94
(78%)

50
(68%)

108
(88%)

69
(92%)

39 (81%) 6 (67%)

ITN use

44
(83%)

10
(67%)

Table 3b: Number of IPT Doses on Malaria Infection, by HIV status
IPT SP Doses

P-value

HIV-positive

0

1

2

No Malaria
Reported

39 (53%)

13 (18%)

21 (29%)

Malaria
Reported

33 (62%)

13 (25%)

9 (17%)

No Malaria
Reported

32 (43%)

15 (20%)

28 (37%)

Malaria
Reported

20 (42%)

17 (35%)

11 (23%)

HIV-positive

33 (62%)

13 (25%)

9 (17%)

HIV-negative

20 (42%)

17 (35%)

11 (23%)

<0.0001

HIV-negative

<0.001

Reported
Malaria

<0.05
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IPT SP Doses

P-value

Hospitalized
for Malaria
HIV-positive

7 (47%)

6 (40%)

2 (13%)

HIV-negative

3 (33%)

6 (66%)

0

<0.0001

Figure 1: Relationship of IPT uptake (%) on Reported Malaria, by HIV-Status

Table 4 shows the relationship between reported malaria infection and HIV-1 RNA
viral load, both peripheral and placental. At delivery, the overall mean peripheral HIV-1
viral load was 5045 copies/mL (SD 16014), and mean placental HIV-1 viral load was
3389 copies/mL (SD 10679). There was no significant difference between HIV-1 RNA
viral load (either placental or peripheral) in subjects reporting malaria during pregnancy
and subjects not reporting malaria.
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Table 4: Relationship of Reported Malaria Exposure to HIV-1 Viral Load and Birth Weight

Delivered

No Malaria Reported

Malaria Reported

P
Value

N=28

N=16

N=12

HIV-1
Peripheral
Viral Load
(mean)

5045 copies/ml(SD
16014)

6385 copies/ml(SD
20001)

2914 copies/ml (SD
4476)

0.26

HIV-1
Placental
Viral Load
(mean)

3390 copies/ml(SD
10679)

3493 copies/ml(SD
12433)

3400 copies/ml (SD
9098)

0.74

Table 5 shows the relationship of ARV treatment during pregnancy to HIV-1 viral
load at delivery. 52% of HIV-1 positive women received Combivir and NVP and had
significantly lower peripheral HIV-1 viral load than the 41% of women who received
NVP only (8979 copies/ml vs 2131 copies/ml, p=0.05).

Table 5: Relationship of ARV during pregnancy to HIV-1 Viral Load at Delivery

NVP only (41%)

Combivir and NVP (52%)

P value

HIV-1 Peripheral Viral
Load (mean)

8979 copies/ml (SD 22822)

2131 copies/ml (SD 7268)

0.05

HIV-1 Placental Viral
Load (mean)

4154 copies/ml (SD13940)

2956 copies/ml (SD 8552)

0.36

Information on malaria parasitemia as determined by microscopy for maternal
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peripheral and placental thick blood films and histopathological analysis of placental
samples are not available at this time.

V.

DISCUSSION
This two-year pilot study investigating the role of malaria on HIV-positive

pregnancy outcomes in Accra, Ghana suggests that, overall, malaria exposure during
pregnancy does not exacerbate HIV in this population. HIV-1 RNA viral loads, both
peripheral and placental, were not significantly different between HIV-positive subjects
who reported malaria infection and who did not report malaria infection (2914
copies/mL, 3400 copies/mL vs 6385 copies/mL, 3493 copies/mL, p=0.26, 0.74).
Prevalence rates of reported malaria among HIV-positive and HIV-negative subjects
were equivalent (41% and 39%), and though almost twice as many HIV-positive subjects
reported hospitalization for malaria (12% vs 7%), this was not statistically significant
(p=0.22). But though no significant relationship between malaria infection and maternal
HIV-1 RNA viral load has been established by this study, there are two important
findings that may influence policy decisions for greater maternal and neonatal risk
reduction during pregnancy. These two findings are the effect of IPT dosing on reported
malaria in this population and the effect of combined ARV therapy on HIV-1 RNA viral
load. These results are not new to the scientific world, but the consistency of these
findings with previous studies helps to validate the data of this pilot study.
With regards to IPT dosing, Table 3b highlights the effectiveness of 2 or more
doses of IPT on reduction of reported malaria in both HIV-positive (17%) and HIVnegative populations (23%) compared to only one dose (25% and 35%) or no uptake of
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IPT (62% and 42%), (p<0.0001, p<0.001). Between the two populations, though the
percentage of HIV-negative subjects receiving two or more doses of IPT (31%) was
higher than the percentage of HIV-positive subjects (23%), this difference was not
statistically significant (p=0.11). In fact, these rates correlate to National Data for uptake
of 2 or more doses of IPT among all Ghanaian pregnant women (30%).16 The significant
effect IPT has on reducing malaria infection in both pregnant populations is reassuring
and suggests that appropriate policy is in place at present, with the emphasis on reaching
more HIV-positive pregnant women. Increasing overall access to IPT, however, is
another challenge.
IPT uptake also seems to be the method of malaria prevention that pregnant women
will more frequently utilize in this study population, but not the only one with positive
results in the HIV-positive pregnant population. Interestingly, among the HIV-positive
subjects who utilized ITB, a significant percentage of subjects did not report malaria
(72%, p<0.0001). This same effect was not seen in the HIV-negative subjects, suggesting
that the use of ITN should be highly encouraged as part of routine care for HIV-positive
pregnant women, perhaps to the point of giving a free bednet to every HIV-positive
pregnant patient. In table 1, HIV-positive pregnant subjects were more likely to have a
lower socioeconomic status based on occupation, education, and housing options, so it is
possible that they are exposed more frequently to malaria than their HIV-negative
counterparts. Thus, it is even more important that ITN use is encouraged during prenatal
care. Overall, however, only 22% of HIV-positive subjects and 12% of HIV-negative
subjects reported using ITN. Understanding the reasoning behind such low utilization
may help improve future use, particularly if low utilization results from lack of access to
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bednets. Providing ITNs, coupled with more aggressive IPT administration, should be the
preferred antimalarial prevention strategy for HIV-positive pregnant women at Korle-Bu
Hospital, and perhaps in all of Western Africa.
Though this project cannot report on MTCT rates in the research population, data
from the Korle-Bu Pediatric Department reports the rate of MTCT from 2007-2009 to be
less than 0.3% (unpublished). As discussed before, risk of MTCT increases 12-fold above
a HIV RNA viral load of 1,000 copies/mL. The mean peripheral (5045, SD 16 014) and
placental (3390, SD 10 679) HIV-1 viral loads detected in the pregnant women of this
project are technically above that cut-off, but the median of both peripheral and placental
HIV-1 viral loads is less than 400 copies/mL. In fact, 21 of the 28 samples (75%) for both
peripheral and placental maternal blood have a HIV RNA viral load less than 1000
copies/mL. The overall low viral load based on this analysis may be responsible for the
low rate of MTCT seen in the Korle-Bu Pediatric department. The low viral loads among
the subjects, in return, can be attributed to basic access to care and availability of
antiretrovirals at the Fevers Unit of Korle-Bu Hospital (over 60% of HIV-positive
subjects received combination therapy prior to delivery and 100% received at least NVP
at delivery). The significant difference in peripheral HIV viral load between subjects
receiving combination therapy prior to delivery and women receiving nevirapine only at
delivery supports this claim (8979 copies/ml vs 2131 copies/ml, p=0.05). Though the low
rate of MTCT may suggest that further efforts to reduce risk of MTCT are not needed,
this should not be the conclusion. Forty percent of HIV-positive women still only receive
the most basic abbreviated ARV regimen at the biggest teaching hospital in West Africa.
More efforts must be made to increase access to combination ARV prior to delivery, just
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as even more PMTCT programs should be established to continue to diagnosis
primigravida women who are unaware of their diagnosis. A startling 60% of women in
this study were diagnosed with HIV during the current pregnancy, most likely due to
increased access to testing.
Another possible reason for low rates of MTCT in this population may be due to
the subtype of HIV-1 that predominates in West Africa. There are 9 major subtypes of
HIV-1 (A,B,C,D,F,G,H,J,K) and 14 major recombinant forms. Epidemiological studies
have shown that the different subtypes have discrete global distributions.43 For example,
subtype C accounts for more than 50% of all HIV infections and predominates in Eastern
and Southern Africa, home to the worst epidemics. Eastern Africa is also home to
subtype D. Subtype A, on the other hand, is found in West Africa. Several studies have
suggested that subtypes C and D have higher virulence than subtype A, as subjects with
subtype C and D developed AIDS faster than subjects with subtype A.44,

45, 46

Recent

studies have also investigated the association of subtype on MTCT, with heterogenous
results. The majority showed no association between subtype and rates of MTCT, but two
studies in East Africa (Kenya and Tanzania) found that subtype A was less transmissible
than either subtype C or D.47, 48 Therefore, it is possible that subtype is having an effect
on the low rates of MTCT of HIV-1 among the subjects in this study, but many
recombinant subtypes may exist in this population, therefore further research would need
to be done to comment on this relationship. If the HIV subtypes predominating in the
Accra area are low virulence, this may possibly explain the 18% rate of discordance
among the HIV-positive pregnant women and their partners. (Table 2) Again, further
research is needed to comment on this relationship as well. Determining specific subtype
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distribution among the HIV-positive pregnant population could add to the understanding
of another factor influencing MTCT in Ghana.
Without analysis of the placental histopathology for malaria parasitemia presence,
this study cannot definitively speak to the relationship between placental malaria
parasitemia and HIV-1 viral concentration, both peripheral and placental. Determining
placental parasitemia presence, prevalence, and density in the HIV-positive subjects,
according to histopathological analysis, would further identify the role of malaria in
pregnancy among Ghanaian women, specifically its effect on MTCT. Examining the
local cytokine environment in the placentas of the HIV-positive subjects in this study is
also an important next step. Particularly in this population of low transmitters, cytokine
profiles would be very insightful to the interplay between placental malaria and HIV
transmission. Does it protect or promote MTCT? Is there placental breakdown or, in this
specific population, does placental malaria parasitemia reduce risk of MTCT of HIV, as
found by Ayisi et al. 37
Though recent studies have discounted the role of increased anti-VSA IgG as a
protective factor against the adverse maternal and neonatal outcomes of pregnancyassociated malaria, assessing malaria immunity within this population may be interesting.
The study found no significant difference in gravity or parity between women who
reported malaria and women who did not report malaria during their pregnancy,
irrespective of their HIV-status. While this correlates to previous studies on HIV-positive
subjects, it is contrary to studies on HIV-negative women. It is possible that pregnant
Ghanaian women in this population have a high baseline level of immunity to malaria
that nullifies the effect of anti-VSA IgG development or that other factors are at play,
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perhaps local cytokine profiles. Assessing levels of this antibody among both HIVpositive and HIV-negative women could provide further understanding of the role of
malaria in pregnancy in this population.
Whether malaria co-infection increases MTCT of HIV is uncertain in this study, but
the study clearly shows that proper HIV care, access to combination antiretroviral therapy
prior to delivery, and protection from malaria infection in pregnancy with ITN and 2 or
more doses of IPT is of great importance to overall maternal health and reduced vertical
transmission of HIV. Efforts must not stand still with regards to providing care to HIVpositive pregnant women in this population.
Limitations, Challenges, and Reflections
The project was a collaboration between the OB-GYN Department, the Fevers
Unit, the Virology Department, the Microbiology Department, and the Pathology
Department at Korle-Bu Hospital, as well as contributions from The Noguchi Institute
and Yale School of Medicine. The collaboration was an impressive multidisciplinary
undertaking in a resource-limited environment that lacked strong intradepartmental
research infrastructure and history. Though, in practice, communication between all
departments could have been more extensive, it laid the groundwork for future
multidisciplinary research projects.
There were several limitations to this study that could have affected outcome. The
first group of limitations involved the research population. The low prevalence of HIV
among pregnant women in Accra, Ghana provided a small population to assess, even
over a two-year period. The low numbers of HIV-positive pregnant women limited the
power of the study, especially with the high attrition rate of subjects. In addition, the
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timing of the project initiation unfortunately coincided with the dry season in Accra
(October to April) and not the rainy or post-rainy seasons (May to September). It is
possible that the number of pregnant women reporting malaria in this study would have
increased if subjects had been enrolled during the rainy season, thus possibly changing
the results of this study, particularly for the higher socioeconomic HIV-negative
population, who would have been more exposed to malaria.
The second category of limitations, and the major challenge in this study, was the
limited research budget, and the aspects of the protocol affected by it.
Dedicated research personnel were lacking on this project, specifically a dedicated
translator, labor nurse, parasitologist, OB-GYN resident, and pathologist to assist in the
collection and processing of data.
Translation
Not having a consistent translator available on the research project meant that
people unfamiliar with the objectives of the research project or the information to be
obtained were occasionally used. Significant recall and reporting bias could be affecting
the current data.
Incorrect information from the subjects most likely resulted on many occasions due
to language and education barrier with the subjects and translators.

A dedicated

translator would also be able to assist in follow-up of non-English speaking subjects after
recruitment and during labor.
Labor Nurse
In a project that requires analysis of placental architecture and thick film
microscopy of fresh placental blood, the timing of placental processing is extremely
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important. But spending every minute on the labor floor waiting for that placenta is
infeasible. Having a dedicated labor nurse or team of labor nurses paid to collect and
immediately process placentas from HIV-positive pregnant women delivering at KorleBu would have increased placental numbers and increased quality of thick film
preparation of placental blood for microscopy. Though the labor nurses in this project
received a small stipend for their assistance in procuring HIV-positive placentas, the
inexperience with research protocol and infrastructure prevented effective contact with
the main research team when an HIV-positive pregnant woman was ready to deliver. At
the beginning of the project, there was a high attrition rate of saving the placentas by the
nurses, but further contact with the labor floor improved those numbers. If more funds
were available, training could be offered to nurses interested in assisting in the research
project for a small stipend, widespread knowledge of the project could be conveyed, and
the protocol could operate more effectively and efficiently. A labor nurse would also
allow the procurement of HIV-negative placentas matched for age, gravity, parity,
gestational age, and mode of delivery, allowing a true comparison of placental
architecture and cytokine environment between HIV-positive and HIV-negative
pregnancies affected by malaria. This was very difficult to accomplish without nurse
assistance on the labor floor, and thus it was abandoned early in the project.
Parasitology
The art of the thick film is multilayered, requiring just the right amount of blood,
just the right thickness. It also requires high quality Giemsa stain and a dedicated
parasitologist to stain and read the slides. On the streets of Accra, it is not uncommon to
find fake Giemsa stain with the effectiveness of blue dye. Unfortunately, many of the
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slides in this study were stained with this low quality Giemsa. In any malaria study,
perfecting the procedure for thick film preparation and staining is a necessity, but it is
also important to have proper training in this, particularly for a researcher unfamiliar with
this process.
OB-GYN Resident
Though we attempted to utilize the OB-GYN residents as best we could for infant
blood draws and obstetric chart clarifications, having a dedicated OB-GYN resident as a
research assistant would help in catching inconsistencies of information reported in the
chart

(on several occasions, IPT doses had not been documented but the resident

remembered prescribing) and in difficult infant blood draws. A dedicated OB-GYN
resident could also assist in identifying both HIV-positive and HIV-negative subjects and
to inform the rest of the department of ways to assist in the research project. The resident
could also help in 6 month follow-ups for all subjects who delivered at Korle-Bu to
assess maternal health, malaria infection postpartum, and infant HIV-conversion. This
additional data would be very useful, as the effects of pregnancy-associated malaria can
persist 60 days postpartum.
Due to budget restrictions, thick films to test for baseline malaria parasitemia were
not performed at routine ANC visits. If a women complained of malaria symptoms, she
received treatment without documentation of parasitemia. Nearly 35% of all pregnant
women hospitalized for malaria did not have documented thick film assessment, nor
blood hemoglobin levels (data not presented). Having a dedicated OB-GYN assistant
familiar with the system to review charts and follow-up on missing information would
have provided even more data to confirm malaria parasitemia and assess its affect on
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maternal health.
The last category in this section involves the challenges of conducting a research
project in a resource-limited setting on a tight research budget, without any prior
experience. Challenging is the appropriate word. In addition to the budget constraints and
language barrier, the lack of supplies to process the few samples obtained, and the
complications of integrating into a foreign hospital infrastructure, the initial unfamiliarity
with Ghanaian culture stood as the most significant barrier to effective implementation of
the protocol. I say this because once familiar with the ways of being Ghanaian, assistance
can readily be found. Of course, it took me 7 of my 8 months to become adept at
Ghanaian culture, to learn the basics of Twi, the hierarchy of the hospital, the trick to
infant blood draws, and the way to ensure that placentas from all HIV-positive women
delivering at Korle-Bu are saved.
Research in developing nations such as Ghana remind me of the saying, “It may not
be the best way or the right way, but it works.” Using broken needles to draw blood from
the tiny veins of newborn babies and collecting that blood drip by drip in a EDTA tube
may not be the best way, but it works when butterfly needles are scarce. Reusing gloves
to process samples over the course of a week is not ideal, but when you need the new
ones for blood draws on the wards, it works. I am thankful to have experienced that
version of medicine, a version that is a reality for the majority of people in this world. I
am thankful to have begun the process of further research into the effect of malaria on
HIV-positive pregnant women in Accra, Ghana, to have seen, first hand, the vulnerability
of that population. I am thankful to be a part of research efforts to better understand the
mechanisms impacting outcome of HIV-positive pregnancies, to better protect this
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population through increased access to care, and to stop pregnancy from being the “most
dangerous thing a woman can do” throughout this world.
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